Abstracts tagged "Biologics"

Abstract Number: 626 • 2017 ACR/ARHP Annual Meeting
Radiographic Progression of Structural Joint Damage in Patients with Active Psoriatic Arthritis Treated with Ixekizumab over 52 Weeks
Désirée van der Heijde¹, Masato Okada², Chin H. Lee³, Catherine Shuler³, Suchitrita Rathmann³, Chen-Yen Lin³ and Philip J Mease⁴, ¹Leiden University Medical Center, Leiden, Netherlands, ²Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ³Eli Lilly and Company, Indianapolis, IN, ⁴Swedish Medical Center and University of Washington, Seattle, WA
Background/Purpose: Ixekizumab (IXE), an anti-interleukin-17A monoclonal antibody, was shown to be superior to placebo (PBO) in clinical responses and inhibiting the progression of structural joint…
Abstract Number: 1449 • 2017 ACR/ARHP Annual Meeting
Development of a Predictive Score of Successful TNF Inhibitor Tapering in Patients with Rheumatoid Arthritis Remission
Clothilde Barral¹, David Hajage², Bruno Fautrel³, Pierre Lafforgue¹, Florence Tubach² and Thao Pham¹, ¹Rheumatology, APHM, Aix Marseille Univ, Marseille, France, ²APHP, Pitié Salpêtrière Hospital, Département Biostatistics and Public health, Pharmacoepidémiology center (Cephepi), 75018 75013, Paris, France, Paris, France, ³Rheumatology, AP-HP Pitié-Salpêtrière Hospital / Pierre and Marie Curie University Paris 6 GRC-08 (EEMOIS), Paris, France
Background/Purpose: Tapering trials confirmed the feasibility of TNF inhibitors (TNFi) tapering for a relevant proportion of patients in remission and/or low disease activity. However, there…
Abstract Number: 1905 • 2017 ACR/ARHP Annual Meeting
Sustained Response Following Discontinuation of Methotrexate in Patients with Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab: Results from a Randomized Controlled Trial
Joel Kremer¹, William F C Rigby², Nora Singer³, Christine Birchwood⁴, Darcy Gill⁴, William Reiss⁴, Jinglan Pei⁴ and Margaret Michalska⁴, ¹Albany Medical College, Albany, NY, ²Geisel School of Medicine at Dartmouth, Lebanon, NH, ³Case Western Reserve University School of Medicine, Cleveland, OH, ⁴Genentech, Inc., South San Francisco, CA
Background/Purpose: Although methotrexate (MTX) is often administered in combination with biologics for the treatment of rheumatoid arthritis (RA), it may be discontinued due to intolerance…
Abstract Number: 2548 • 2017 ACR/ARHP Annual Meeting
Validation of New Potential Targets for Remission and Low Disease Activity in Psoriatic Arthritis in Patients Treated with Golimumab
Laura C Coates¹, Proton Rahman², Eliofotisti Psaradellis³, Emmanouil Rampakakis³, Brendan Osborne⁴, Allen J Lehman⁵ and Francois Nantel⁴, ¹LIRMM, University of Leeds, Leeds, United Kingdom, ²Rheumatology, St Claires Mercy Hospital, St Johns, NF, Canada, ³JSS Medical Research, Montreal, QC, Canada, ⁴Medical Affairs, Janssen Inc., Toronto, ON, Canada, ⁵Janssen Inc., Toronto, ON, Canada
Background/Purpose: Treat to target recommendations in PsA state that the target of treatment should be remission or low disease activity (LDA). So far, the only…
Abstract Number: 366 • 2017 ACR/ARHP Annual Meeting
Short-Term Outcomes in Patients with Systemic-Onset Juvenile Idiopathic Arthritis Treated with Either Tocilizumab or Anakinra in a Real-World Setting in the United Kingdom
Lianne Kearsley-Fleet¹, Diederik De Cock¹, Eileen Baildam², Michael W. Beresford³, Helen E. Foster⁴, Taunton R. Southwood⁵, Wendy Thomson^6,7 and Kimme L. Hyrich^1,6, ¹Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, ²Clinical Academic Department of Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom, ³Alder Hey Children's NHS Foundation Trust Hospital, Institute of Translational Medicine (Child Health), University of Liverpool, Liverpool, United Kingdom, ⁴Institute of Cellular Medicine and Paediatric Rheumatology, Newcastle University and Great North Children's Hospital, Newcastle Upon Tyne, United Kingdom, ⁵Institute of Child Health, University of Birmingham and Birmingham Children's Hospital, Birmingham, United Kingdom, ⁶National Institute of Health Research Manchester Musculoskeletal Biomedical Research Centre, Central Manchester NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁷Arthritis Research UK Centre for Genetics and Genomics, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom
Background/Purpose: Juvenile idiopathic arthritis (JIA) comprises 7 ILAR categories, but systemic-onset JIA (sJIA) appears to be distinct in genetic background and pathogenesis from the other…
Abstract Number: 637 • 2017 ACR/ARHP Annual Meeting
The Effect of Biologic Therapies on the Gut Microbial Composition in Psoriatic Arthritis
Julia Manasson¹, Carles Ubeda², Lu Yang³, Melania Fanok⁴, Gary E. Solomon¹, Soumya M. Reddy⁵, Sergei Koralov⁶, Jose C. Clemente⁷ and Jose U. Scher^1,4, ¹Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ²Institute for Research in Public Health, Valencia, Spain, ³New York University School of Medicine, New York, NY, ⁴New York University School of Medicine, New York, NY, ⁵Department of Medicine, Division of Rheumatology *contributed equally, New York University School of Medicine, New York, NY, ⁶Pathology, New York University School of Medicine, New York, NY, ⁷Department of Genetics and Genomic Sciences, Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous inflammatory arthritis affecting multiple clinical domains. If left untreated, it has the potential for significant morbidity and disability.…
Abstract Number: 1460 • 2017 ACR/ARHP Annual Meeting
Predictive Factors Associated with Successful Down-Titration of Biologics for Rheumatoid Arthritis Patients in Clinical Practice
Takaaki Komiya¹, Kaoru Minegishi-Takase², Natsuki Sakurai¹, Yuichiro Sato¹, Hideto Nagai³, Naoki Hamada³, Yumiko Sugiyama³, Naomi Tsuchida¹, Yutaro Soejima³, Yosuke Kunishita³, Hiroto Nakano³, Daiga Kishimoto³, Koji Kobayashi², Reikou Kamiyama³, Ryusuke Yoshimi³, Yukiko Asami³, Yohei Kirino³, Shigeru Ohno⁴ and Hideaki Nakajima³, ¹Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ²Center for Rheumatic Diseases, Yokohama City University Medical Center, Yokohama, Japan, ³Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ⁴Center for Rheumatic Disease, Yokohama City University Medical Center, Yokohama, Japan
Background/Purpose: Randomized clinical trials have shown that if a patient is in sustained remission, biological disease-modifying anti rheumatic drugs (bDMARDs) therapy can be tapered in…
Abstract Number: 1966 • 2017 ACR/ARHP Annual Meeting
Risk of Tuberculosis in Biologic Users for Rheumatic Diseases: Results from the South African Biologics Registry
Clive Pettipher¹ and Romela Benitha², ¹Rheumatology, Private Practice, Stellenbosch, South Africa, ²Rheumatology, Private Practive, Johannesburg, South Africa
Background/Purpose: To evaluate the rate of tuberculosis (TB) in biologic users for rheumatic diseases in South Africa, a TB endemic country, the effectiveness of our…
Abstract Number: 2549 • 2017 ACR/ARHP Annual Meeting
Achievement of Minimal Disease Activity Is Associated with Improvements in Health-Related Quality of Life and Productivity in Psoriatic Arthritis Patients
Laura C Coates¹, Ana-Maria Orbai², Julie Birt³, Lisa Kerr³, Olivier Benichou³ and Philip S. Helliwell⁴, ¹University of Oxford, Leeds, Great Britain, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Eli Lilly and Company, Indianapolis, IN, ⁴School of Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: Treatment goals in psoriatic arthritis (PsA) are moving toward attainment of absolute therapeutic thresholds rather than relative improvement. Minimal disease activity (MDA), a composite…
Abstract Number: 433 • 2017 ACR/ARHP Annual Meeting
Predictors of Earlier Biologic Initiation Among Patients with Rheumatoid Arthritis Starting Methotrexate
Michael D. George¹, Brian Sauer², Chia-Chen Teng, MS², Grant Cannon², Bryant R. England³, Gail S. Kerr⁴, Ted R. Mikuls⁵ and Joshua Baker⁶, ¹Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ³Division of Rheumatology & Immunology, Department of Internal Medicine, Nebraska-Western IA VA Health Care System & University of Nebraska Medical Center, Omaha, NE, ⁴VAMC, Georgetown University, Washington, DC, ⁵Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁶Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Biologic therapy for the treatment of RA has increased dramatically and has substantially increased costs of care. This study aimed to identify factors associated…
Abstract Number: 925 • 2017 ACR/ARHP Annual Meeting
Open-Source Conensus-Based Models to Improve the Cost-Effectiveness of Rheumatology Care
Devin Incerti¹, Jeffrey R. Curtis², Maria Lorenzi¹ and Jeroen Jansen¹, ¹Innovation and Value Initiative, Oakland, CA, ²Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The treatment and prognosis of moderate to severe rheumatoid arthritis has improved considerably due to the advent of biological therapies. But at the same…
Abstract Number: 1464 • 2017 ACR/ARHP Annual Meeting
Relation of HLA-DRB1 Genotype to the Efficacies of Abatacept and Tocilizumab in Patients with Rheumatoid Arthritis
Kensuke Oryoji, The Center for Rheumatology, Matsuyama Red Cross Hospital, Ehime, Japan
Background/Purpose: To investigate whether clinical efficacy of abatacept (ABT) and tocilizumab (TCZ) differs depending on whether or not HLA-DRB1 Shared Epitope (SE) is present in…
Abstract Number: 2024 • 2017 ACR/ARHP Annual Meeting
Prediction of Response to Certolizumab-Pegol in Rheumatoid Arthritis By Functional MRI of the Brain – an Interim Analysis of an Ongoing Investigator Initiated Phase III Trial
Hannah Schenker¹, Andreas Hess², Laura Konerth², Marina Sergeeva², Jutta Prade², Arnd Kleyer¹, Michaela Reiser¹, Axel J. Hueber¹, Matthias Englbrecht¹, Eugen Feist³, Reinhard Voll⁴, Bettina Bannert⁴, C Baerwald⁵, Julie Rösch⁶, Arnd Dörfler⁷, José António P. da Silva⁸, Nemanja Damjanov⁹, Georg Schett¹ and Juergen Rech¹, ¹Department of Medicine 3, Rheumatology and Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²Institute of Pharmacology and Toxicology, University of Erlangen-Nuremberg, Erlangen, Germany, ³Department of Rheumatology and Clinical Immunology, Charité, Berlin, Berlin, Germany, ⁴Clinic for Rheumatology and Clinical Immunology, Medical University of Freiburg, Germany, Freiburg, Germany, ⁵Department of Rheumatology, University of Leipzig, Germany, Leipzig, Germany, ⁶Department of Neuroradiology, University of Erlangen-Nuremberg, Germany, Erlangen, Germany, ⁷Department of Neuroradiology, University of Erlangen-Nuremberg, Germany, e, Germany, ⁸Rheumatology, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, ⁹Institute of Rheumatology, Belgrade University School of Medicine, Belgrade, Serbia
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) signify a major advance in the treatment of rheumatoid arthritis (RA). However, treatment success initially remains uncertain as one…
Abstract Number: 2591 • 2017 ACR/ARHP Annual Meeting
Association of Smoking and Cutaneous Manifestations in Systemic Lupus Erythematosus (SLE): Post-Hoc Results from Phase IIb Studies of Anifrolumab and Sifalimumab
Victoria P Werth¹, Gabor Illei², Gabriel Abreu³, Liangwei Wang² and Warren Greth², ¹University of Pennsylvania and the VA Medical Center, Philadelphia, PA, ²MedImmune, Gaithersburg, MD, ³AstraZeneca, Gothenburg, Sweden
Background/Purpose: Studies have demonstrated an association between smoking and more severe cutaneous lupus erythematosus, resulting in decreased health-related quality of life and treatment response.1 We…
Abstract Number: 516 • 2017 ACR/ARHP Annual Meeting
Efficacy of Adding Iguratimod Therapy in Rheumatoid Arthritis　Patients Who Had Inadequate Response to Biologic Dmards
Toshiaki Miyamoto, Rheumatology, SEIREI HAMAMATSU GENERAL HOSPITAL, Hamamatsu, Japan
Background/Purpose: Iguratimod (IGU) was approved in June 2012 and recommended by JCR guideline 2014 in the treatment of rheumatoid arthritis (RA). Although there have been…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].